KRAS and pancreatic neoplasm: Further investigations revealed that inhibiting 5-Lox through MK591 or shRNA significantly reduced the activation of key components in the K-Ras signaling pathway, notably c-Raf and ERKs, which are critical in pancreatic cancer progression.